AIDX debuts on Nasdaq with $40M equity line, material control weaknesses, and $3.7M loss

Filed March 31, 2026 · Period ending December 31, 2025 · ~2 min read

Key Changes

• high

  Company disclosed material weaknesses in financial controls due to insufficient accounting staff and lack of GAAP expertise for complex transactions. Management cannot assure timely remediation, creating risk of reporting errors and delayed SEC filings.

  Controls & Procedures verify on EDGAR →
• high

  Management states continuation as going concern depends on revenue growth exceeding spending and external financing. Company had $1.0M cash at year-end and raised $5M via Series E preferred plus $250K convertible debt to fund operations.

  MD&A: Liquidity verify on EDGAR →
• high

  Revenue grew 17% to $2.0M driven by OneTest cancer screening (88% of sales), but company remains unprofitable with $3.7M net loss. Operating expenses fell 30% through marketing optimization and headcount reductions, narrowing loss from $5.6M in 2024.

  MD&A: Results of Operations verify on EDGAR →